Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Coleman Website

C. Norman Coleman, M.D.

Selected Publications

1)  Simone CB, John-Aryankalayil M, Palayoor ST, Makinde AY, Cerna D, Falduto MT, Magnuson SR, Coleman CN.
mRNA Expression Profiles for Prostate Cancer following Fractionated Irradiation Are Influenced by p53 Status.
Transl Oncol. 6: 573-85, 2013.
2)  Makinde AY, John-Aryankalayil M, Palayoor ST, Cerna D, Coleman CN.
Radiation survivors: understanding and exploiting the phenotype following fractionated radiation therapy.
Mol. Cancer Res. 11: 5-12, 2013.
3)  John-Aryankalayil M, Palayoor ST, Makinde AY, Cerna D, Simone CB, Falduto MT, Magnuson SR, Coleman CN.
Fractionated Radiation Alters Oncomir and Tumor Suppressor miRNAs in Human Prostate Cancer Cells.
Radiat Res. 178: 105-17, 2012.
4)  Palayoor ST, J-Aryankalayil M, Makinde AY, Cerna D, Falduto MT, Magnuson SR, Coleman CN.
Gene expression profile of coronary artery cells treated with nonsteroidal anti-inflammatory drugs reveals off-target effects.
J. Cardiovasc. Pharmacol. 59: 487-99, 2012.
5)  Coleman CN.
Fukushima and the future of radiation research.
Radiat. Res. 179: 1-8, 2013.
6)  Prasanna A, Ahmed MM, Mohiuddin M, Coleman CN.
Exploiting sensitization windows of opportunity in hyper and hypo-fractionated radiation therapy.
J Thorac Dis. 6: 287-302, 2014.
7)  Yoo SS, Jorgensen TJ, Kennedy AR, Boice Jr JD, Shapiro A, Hu TC, Moyer BR, Grace MB, Kelloff GJ, Fenech M, Prasanna PG, Coleman CN.
Mitigating the risk of radiation-induced cancers: limitations and paradigms in drug development.
J Radiol Prot. 34: R25-R52, 2014.
8)  Sullivan JM, Prasanna PG, Grace MB, Wathen LK, Wallace RL, Koerner JF, Coleman CN.
Assessment of biodosimetry methods for a mass-casualty radiological incident: medical response and management considerations.
Health Phys. 105: 540-54, 2013.
9)  Liu FF, Okunieff P, Bernhard EJ, Stone HB, Yoo S, Coleman CN, Vikram B, Brown M, Buatti J, Guha C.
Lessons learned from radiation oncology clinical trials.
Clin. Cancer Res. 19: 6089-100, 2013.
10)  Lawrence YR, Vikram B, Dignam JJ, Chakravarti A, Machtay M, Freidlin B, Takebe N, Curran WJ, Bentzen SM, Okunieff P, Coleman CN, Dicker AP.
NCI-RTOG translational program strategic guidelines for the early-stage development of radiosensitizers.
J. Natl. Cancer Inst. 105: 11-24, 2013.
11)  Lin SH, George TJ, Ben-Josef E, Bradley J, Choe KS, Edelman MJ, Guha C, Krishnan S, Lawrence TS, Le Q, Lu B, Mehta M, Peereboom D, Sarkaria J, Seong J, Wang D, Welliver MX, Coleman CN, Vikram B, Yoo S, Chung CH.
Opportunities and Challenges in the Era of Molecularly Targeted Agents and Radiation Therapy.
J. Natl. Cancer Inst. 105: 686-93, 2013.
12)  Coleman CN, Blumenthal DJ, Casto CA, Alfant M, Simon SL, Remick AL, Gepford HJ, Bowman T, Telfer JL, Blumenthal PM, Noska MA.
Recovery and resilience after a nuclear power plant disaster: a medical decision model for managing an effective, timely, and balanced response.
Disaster Med Public Health Prep. 7: 136-45, 2013.
13)  Coleman CN, Whitcomb RC, Miller CW, Noska MA.
Commentary on the combined disaster in Japan.
Radiat. Res. 177: 15-7, 2012.
14)  Coleman CN, Lurie N.
Emergency medical preparedness for radiological/nuclear incidents in the United States.
J Radiol Prot. 32: N27-32, 2012.
15)  Cerna D, Li H, Flaherty S, Takebe N, Coleman CN, Yoo SS.
Inhibition of Nicotinamide Phosphoribosyltransferase (NAMPT) activity by the small molecule GMX1778 regulates ROS-mediated cytotoxicity in a p53- and Nicotinic Acid Phosphoribosyltransferase1 (NAPRT1)-dependent manner.
J Biol Chem. 287: 22408-17, 2012.
16)  Coleman CN, Adams S, Adrianopoli C, Ansari A, Bader JL, Buddemeier B, Caro JJ, Casagrande R, Case C, Caspary K, Chang AS, Chang HF, Chao N, Cliffer KD, Confer D, Deitchman S, Derenzo EG, Dobbs A, Dodgen D, Donnelly EH, Gorman S, Grace MB, Hatchett R, Hick JL, Hrdina C, Jones R, Kane E, Knebel A, Koerner JF, Laffan AM, Larson L, Livinski A, Mackinney J, Maidment BW, Manning R, Marinissen MJ, Martin C, Michael G, Murrain-Hill P, Nemhauser JB, Norwood AE, Nystrom S, Raheem M, Redlener I, Sheehan K, Simon SL, Taylor TP, Toner E, Wallace KS, Wieder J, Weinstock DM, Wiley AL, Yeskey K.
Medical planning and response for a nuclear detonation: a practical guide.
Biosecur Bioterror. 10: 346-71, 2012.
17)  Prasanna PG, Stone HB, Wong RS, Capala J, Bernhard EJ, Vikram B, Coleman CN.
Normal tissue protection for improving radiotherapy: Where are the Gaps?.
Transl Cancer Res. 1: 35-48, 2012.
18)  Love RR, Ginsburg OM, Coleman CN.
Public health oncology: a framework for progress in low- and middle-income countries.
Ann. Oncol. 23: 3040-5, 2012.
19)  Bekelman JE, Deye JA, Vikram B, Bentzen SM, Bruner D, Curran WJ, Dignam J, Efstathiou JA, Fitzgerald TJ, Hurkmans C, Ibbott GS, Lee JJ, Merchant TE, Michalski J, Palta JR, Simon R, Ten Haken RK, Timmerman R, Tunis S, Coleman CN, Purdy J.
Redesigning Radiotherapy Quality Assurance: Opportunities to Develop an Efficient, Evidence-Based System to Support Clinical Trials-Report of the National Cancer Institute Work Group on Radiotherapy Quality Assurance.
Int J Radiat Oncol Biol Phys. 83: 782-90, 2012.
20)  Coleman CN, Hrdina C, Casagrande R, Cliffer KD, Mansoura MK, Nystrom S, Hatchett R, Caro JJ, Knebel AR, Wallace KS, Adams SA.
User-managed inventory: an approach to forward-deployment of urgently needed medical countermeasures for mass-casualty and terrorism incidents.
Disaster Med Public Health Prep. 6: 408-14, 2012.
21)  Petereit DG, Guadagnolo BA, Wong R, Coleman CN.
Addressing Cancer Disparities Among American Indians through Innovative Technologies and Patient Navigation: The Walking Forward Experience.
Front Oncol. 1: 11, 2011.
22)  Knebel AR, Coleman CN, Cliffer KD, Murrain-Hill P, McNally R, Oancea V, Jacobs J, Buddemeier B, Hick JL, Weinstock DM, Hrdina CM, Taylor T, Matzo M, Bader JL, Livinski AA, Parker G, Yeskey K.
Allocation of scarce resources after a nuclear detonation: setting the context.
Disaster Med Public Health Prep. 5 Suppl 1: S20-31, 2011.
23)  Romm H, Wilkins RC, Coleman CN, Lillis-Hearne PK, Pellmar TC, Livingston GK, Awa AA, Jenkins MS, Yoshida MA, Oestreicher U, Prasanna PG.
Biological dosimetry by the triage dicentric chromosome assay: potential implications for treatment of acute radiation syndrome in radiological mass casualties.
Radiat. Res. 175: 397-404, 2011.
24)  Mettler FA, Brenner D, Coleman CN, Kaminski JM, Kennedy AR, Wagner LK.
Can radiation risks to patients be reduced without reducing radiation exposure? The status of chemical radioprotectants.
AJR Am J Roentgenol. 196: 616-8, 2011.
25)  Ryan JL, Krishnan S, Movsas B, Coleman CN, Vikram B, Yoo SS.
Decreasing the adverse effects of cancer therapy: an NCI Workshop on the preclinical development of radiation injury mitigators/protectors.
Radiat. Res. 176: 688-91, 2011.
26)  Movsas B, Vikram B, Hauer-Jensen M, Moulder JE, Basch E, Brown SL, Kachnic LA, Dicker AP, Coleman CN, Okunieff P.
Decreasing the adverse effects of cancer therapy: National Cancer Institute guidance for the clinical development of radiation injury mitigators.
Clin. Cancer Res. 17: 222-8, 2011.
27)  Coleman CN, Simon SL, Noska MA, Telfer JL, Bowman T.
Disaster preparation: lessons from Japan.
Science. 332: 1379, 2011.
28)  Dainiak N, Gent RN, Carr Z, Schneider R, Bader J, Buglova E, Chao N, Coleman CN, Ganser A, Gorin C, Hauer-Jensen M, Huff LA, Lillis-Hearne P, Maekawa K, Nemhauser J, Powles R, Schünemann H, Shapiro A, Stenke L, Valverde N, Weinstock D, White D, Albanese J, Meineke V.
First global consensus for evidence-based management of the hematopoietic syndrome resulting from exposure to ionizing radiation.
Disaster Med Public Health Prep. 5: 202-12, 2011.
29)  Shay JW, Cucinotta FA, Sulzman FM, Coleman CN, Minna JD.
From mice and men to earth and space: joint NASA-NCI workshop on lung cancer risk resulting from space and terrestrial radiation.
Cancer Res. 71: 6926-9, 2011.
30)  Hick JL, Weinstock DM, Coleman CN, Hanfling D, Cantrill S, Redlener I, Bader JL, Murrain-Hill P, Knebel AR.
Health care system planning for and response to a nuclear detonation.
Disaster Med Public Health Prep. 5 Suppl 1: S73-88, 2011.
31)  Hatchett R, Coleman CN, Lurie N.
Health risks of accidents at nuclear power plants.
N. Engl. J. Med. 365: 963-4; author reply 964, 2011.
32)  Dainiak N, Gent RN, Carr Z, Schneider R, Bader J, Buglova E, Chao N, Coleman CN, Ganser A, Gorin C, Hauer-Jensen M, Huff LA, Lillis-Hearne P, Maekawa K, Nemhauser J, Powles R, Schünemann H, Shapiro A, Stenke L, Valverde N, Weinstock D, White D, Albanese J, Meineke V.
Literature review and global consensus on management of acute radiation syndrome affecting nonhematopoietic organ systems.
Disaster Med Public Health Prep. 5: 183-201, 2011.
33)  Murrain-Hill P, Coleman CN, Hick JL, Redlener I, Weinstock DM, Koerner JF, Black D, Sanders M, Bader JL, Forsha J, Knebel AR.
Medical response to a nuclear detonation: creating a playbook for state and local planners and responders.
Disaster Med Public Health Prep. 5 Suppl 1: S89-97, 2011.
34)  Coleman CN, Knebel AR, Lurie N.
Preparing and planning for a catastrophic incident of a nuclear detonation. Foreword.
Disaster Med Public Health Prep. 5 Suppl 1: S11-2, 2011.
35)  DiCarlo AL, Maher C, Hick JL, Hanfling D, Dainiak N, Chao N, Bader JL, Coleman CN, Weinstock DM.
Radiation injury after a nuclear detonation: medical consequences and the need for scarce resources allocation.
Disaster Med Public Health Prep. 5 Suppl 1: S32-44, 2011.
36)  Caro JJ, DeRenzo EG, Coleman CN, Weinstock DM, Knebel AR.
Resource allocation after a nuclear detonation incident: unaltered standards of ethical decision making.
Disaster Med Public Health Prep. 5 Suppl 1: S46-53, 2011.
37)  Coleman CN, Knebel AR, Hick JL, Weinstock DM, Casagrande R, Caro JJ, DeRenzo EG, Dodgen D, Norwood AE, Sherman SE, Cliffer KD, McNally R, Bader JL, Murrain-Hill P.
Scarce resources for nuclear detonation: project overview and challenges.
Disaster Med Public Health Prep. 5 Suppl 1: S13-9, 2011.
38)  Grace MB, Cliffer KD, Moyer BR, Coleman CN, Prasher JM, Hatchett R, Mercier J, Manning RG, Bader JL, Disbrow GL, Kovacs GR.
Health Phys. 101: 238-247, 2011.
39)  Coleman CN, Weinstock DM, Casagrande R, Hick JL, Bader JL, Chang F, Nemhauser JB, Knebel AR.
Triage and treatment tools for use in a scarce resources-crisis standards of care setting after a nuclear detonation.
Disaster Med Public Health Prep. 5 Suppl 1: S111-21, 2011.
40)  Caro JJ, Coleman CN, Knebel A, DeRenzo EG.
Unaltered ethical standards for individual physicians in the face of drastically reduced resources resulting from an improvised nuclear device event.
J Clin Ethics. 22: 33-41, 2011.
41)  Casagrande R, Wills N, Kramer E, Sumner L, Mussante M, Kurinsky R, McGhee P, Katz L, Weinstock DM, Coleman CN.
Using the model of resource and time-based triage (MORTT) to guide scarce resource allocation in the aftermath of a nuclear detonation.
Disaster Med Public Health Prep. 5 Suppl 1: S98-110, 2011.
42)  Davids MS, Case C, Hornung R, Chao NJ, Chute JP, Coleman CN, Weisdorf D, Confer DL, Weinstock DM.
Assessing surge capacity for radiation victims with marrow toxicity.
Biol Blood Marrow Transplant. 16: 1436-41, 2010.
43)  John-Aryankalayil M, Palayoor ST, Cerna D, Simone CB, Falduto MT, Magnuson SR, Coleman CN.
Fractionated Radiation Therapy Can Induce a Molecular Profile for Therapeutic Targeting.
Radiat Res. 174: 446-58, 2010.
44)  Grace MB, Moyer BR, Prasher J, Cliffer KD, Ramakrishnan N, Kaminski J, Coleman CN, Manning RG, Maidment BW, Hatchett R.
Rapid radiation dose assessment for radiological public health emergencies: roles of NIAID and BARDA.
Health Phys. 98: 172-8, 2010.
45)  Coleman CN, Glatstein E.
The road not taken and choices in radiation oncology.
Oncologist. 15: 332-7, 2010.
46)  Vikram B, Coleman CN, Deye JA.
Current status and future potential of advanced technologies in radiation oncology. Part 1. Challenges and resources.
Oncology. 23: 279-83, 2009.
47)  Vikram B, Coleman CN, Deye JA.
Current status and future potential of advanced technologies in radiation oncology. Part 2. State of the science by anatomic site.
Oncology. 23: 380-5, 2009.
48)  Kamrava M, Tsang KY, Madan RA, Kaushal A, Coleman CN, Gulley J.
Long-term survival and PSA control with radiation and immunotherapy for node positive prostate cancer.
Clin. Dev. Immunol. 2009: 363914, 2009.
49)  Wasserman TH, Coleman CN.
Mentors, mensches, and models.
Int. J. Radiat. Oncol. Biol. Phys. 73: 974-5, 2009.
50)  John-Aryankalayil M, Palayoor ST, Cerna D, Falduto MT, Magnuson SR, Coleman CN.
NS-398, ibuprofen, and cyclooxygenase-2 RNA interference produce significantly different gene expression profiles in prostate cancer cells.
Mol. Cancer Ther. 8: 261-73, 2009.
51)  Coleman CN, Parker GW.
Radiation terrorism: what society needs from the radiobiology-radiation protection and radiation oncology communities.
J Radiol Prot. 29: A159-69, 2009.
52)  Fliedner TM, Chao NJ, Bader JL, Boettger A, Case C, Chute J, Confer DL, Ganser A, Gorin NC, Gourmelon P, Graessle DH, Krawisz R, Meineke V, Niederwieser D, Port M, Powles R, Sirohi B, Weinstock DM, Wiley A, Coleman CN.
Stem cells, multiorgan failure in radiation emergency medical preparedness: a U.S./European Consultation Workshop.
Stem Cells. 27: 1205-11, 2009.
53)  Hrdina CM, Coleman CN, Bogucki S, Bader JL, Hayhurst RE, Forsha JD, Marcozzi D, Yeskey K, Knebel AR.
Prehosp Disaster Med. 24: 167-78, 2009.
54)  Simone NL, Menard C, Soule BP, Albert PS, Guion P, Smith S, Godette D, Crouse NS, Sciuto LC, Cooley-Zgela T, Camphausen K, Coleman CN, Singh AK.
Intrarectal amifostine during external beam radiation therapy for prostate cancer produces significant improvements in Quality of Life measured by EPIC score.
Int. J. Radiat. Oncol. Biol. Phys. 70: 90-5, 2008.
55)  Coleman CN, Hrdina C, Bader JL, Norwood A, Hayhurst R, Forsha J, Yeskey K, Knebel A.
Medical Response to a Radiologic/Nuclear Event: Integrated Plan From the Office of the Assistant Secretary for Preparedness and Response, Department of Health and Human Services.
Ann Emerg Med. 53: 213-22, 2008.
56)  Palayoor ST, Mitchell JB, Cerna D, Degraff W, John-Aryankalayil M, Coleman CN.
PX-478, an inhibitor of hypoxia-inducible factor-1alpha, enhances radiosensitivity of prostate carcinoma cells.
Int. J. Cancer. 123: 2430-7, 2008.
57)  Weinstock DM, Case C, Bader JL, Chao NJ, Coleman CN, Hatchett RJ, Weisdorf DJ, Confer DL.
Radiologic and nuclear events: contingency planning for hematologists/oncologists.
Blood. 111: 5440-5, 2008.
58)  Tsai MH, Cook JA, Chandramouli GV, DeGraff W, Yan H, Zhao S, Coleman CN, Mitchell JB, Chuang EY.
Gene expression profiling of breast, prostate, and glioma cells following single versus fractionated doses of radiation.
Cancer Res. 67: 3845-52, 2007.
59)  Chen Y, Trotti A, Coleman CN, Machtay M, Mirimanoff RO, Hay J, O'brien PC, El-Gueddari B, Salvajoli JV, Jeremic B.
Adverse event reporting and developments in radiation biology after normal tissue injury: International Atomic Energy Agency consultation.
J. Urol. 175: 1442-51, 2006.
60)  Menard C, Johann D, Lowenthal M, Muanza T, Sproull M, Ross S, Gulley J, Petricoin E, Coleman C, Whiteley G, Liotta L, Camphausen K.
Discovering clinical biomarkers of ionizing radiation exposure with serum proteomic analysis.
Cancer Res. 66: 1844-50, 2006.
61)  Singh AK, Guion P, Susil RC, Citrin DE, Ning H, Miller RW, Ullman K, Smith S, Crouse NS, Godette DJ, Stall BR, Coleman CN, Camphausen K, Menard C.
Early observed transient prostate-specific antigen elevations on a pilot study of external beam radiation therapy and fractionated MRI guided High Dose Rate brachytherapy boost.
Radiat Oncol. 1: 28, 2006.
62)  Ullman KL, Ning H, Susil RC, Ayele A, Jocelyn L, Havelos J, Guion P, Xie H, Li G, Arora BC, Cannon A, Miller RW, Coleman CN, Camphausen K, Menard C.
Intra- and inter-radiation therapist reproducibility of daily isocenter verification using prostatic fiducial markers.
Radiat Oncol. 1: 2, 2006.
63)  Singh AK, Menard C, Guion P, Simone NL, Smith S, Crouse NS, Godette DJ, Cooley-Zgela T, Sciuto LC, Coleman J, Pinto P, Albert PS, Camphausen K, Coleman CN.
Intrarectal amifostine suspension may protect against acute proctitis during radiation therapy for prostate cancer: a pilot study.
Int. J. Radiat. Oncol. Biol. Phys. 65: 1008-13, 2006.
64)  Tsai MH, Chen X, Chandramouli GV, Chen Y, Yan H, Zhao S, Keng P, Liber HL, Coleman CN, Mitchell JB, Chuang EY.
Transcriptional responses to ionizing radiation reveal that p53R2 protects against radiation-induced mutagenesis in human lymphoblastoid cells.
Oncogene. 25: 622-32, 2006.
65)  Susil RC, Menard C, Krieger A, Coleman JA, Camphausen K, Choyke P, Fichtinger G, Whitcomb LL, Coleman CN, Atalar E.
Transrectal prostate biopsy and fiducial marker placement in a standard 1.5T magnetic resonance imaging scanner.
J Urol. 175(1). 113-20, 2006.
66)  Li G, Xie H, Ning H, Capala J, Arora BC, Coleman CN, Camphausen K, Miller RW.
A novel 3D volumetric voxel registration technique for volume-view-guided image registration of multiple imaging modalities.
Int J Radiat Oncol Biol Phys. 63: 261-73, 2005.
67)  Menard C, Susil RC, Choyke P, Coleman J, Grubb R, Gharib A, Krieger A, Guion P, Thomasson D, Ullman K, Gupta S, Espina V, Liotta L, Petricoin E, Fitchtinger G, Whitcomb LL, Atalar E, Coleman CN, Camphausen K.
An interventional magnetic resonance imaging technique for the molecular characterization of intraprostatic dynamic contrast enhancement.
Mol Imaging. 4: 63-6, 2005.
68)  Gulley JL, Arlen PM, Bastian A, Morin S, Marte J, Beetham P, Tsang K, Yokokawa J, Hodge JW, Menard C, Camphausen K, Coleman CN, Sullivan F, Steinberg SM, Schlom J, Dahut W.
Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer.
Clin Cancer Res. 11: 3353-62, 2005.
69)  Muanza TM, Albert PS, Smith S, Godette D, Crouse NS, Cooley-Zgela T, Sciuto L, Camphausen K, Coleman CN, Menard C.
Comparing measures of acute bowel toxicity in patients with prostate cancer treated with external beam radiation therapy.
Int. J. Radiat. Oncol. Biol. Phys. 62: 1316-21, 2005.
70)  Tsai MH, Yan H, Chen X, Chandramouli GV, Zhao S, Coffin D, Coleman CN, Mitchell JB, Chuang EY.
Evaluation of hybridization conditions for spotted oligonucleotide-based DNA microarrays.
Mol Biotechnol. 29: 221-4, 2005.
71)  Muanza TM, Cotrim AP, McAuliffe M, Sowers AL, Baum BJ, Cook JA, Feldchtein F, Amazeen P, Coleman CN, Mitchell JB.
Evaluation of radiation-induced oral mucositis by optical coherence tomography.
Clin. Cancer Res. 11: 5121-7, 2005.
72)  Citrin D, Ning H, Guion P, Li G, Susil RC, Miller RW, Lessard E, Pouliot J, Huchen X, Capala J, Coleman CN, Camphausen K, Menard C.
Inverse treatment planning based on MRI for HDR prostate brachytherapy.
Int. J. Radiat. Oncol. Biol. Phys. 61: 1267-75, 2005.
73)  Palayoor ST, Arayankalayil MJ, Shoaibi A, Coleman CN.
Radiation sensitivity of human carcinoma cells transfected with small interfering RNA targeted against cyclooxygenase-2.
Clin. Cancer Res. 11: 6980-6, 2005.
74)  Kudo-Saito C, Schlom J, Camphausen K, Coleman CN, Hodge JW.
The requirement of multimodal therapy (vaccine, local tumor radiation, and reduction of suppressor cells) to eliminate established tumors.
Clin. Cancer Res. 11: 4533-44, 2005.
75)  Petereit DG, Rogers D, Burhansstipanov L, Kaur J, Govern F, Howard SP, Osburn CH, Coleman CN, Fowler JF, Chappell R, Mehta MP.
Walking forward: the South Dakota Native American project.
J Cancer Educ. 20: 65-70, 2005.
76)  Wallner PE, Coleman CN, Brechbiel M, Milenic D, Tripuraneni P.
Are radiation oncologists serious about systemic radiation therapy and if not, should we be?.
Int J Radiat Oncol Biol Phys. 60: 1-2, 2004.
77)  Palayoor ST, Burgos MA, Shoaibi A, Tofilon PJ, Coleman CN.
Effect of radiation and ibuprofen on normoxic renal carcinoma cells overexpressing hypoxia-inducible factors by loss of von Hippel-Lindau tumor suppressor gene function.
Clin Cancer Res. 10: 4158-64, 2004.
78)  Chakraborty M, Abrams SI, Coleman CN, Camphausen K, Schlom J, Hodge JW.
External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing.
Cancer Res. 64: 4328-37, 2004.
79)  Coleman CN.
International Conference on Translational Research ICTR 2003 Conference Summary: marshalling resources in a complex time.
Int. J. Radiat. Oncol. Biol. Phys. 58: 307-19, 2004.
80)  Camphausen K, Menard C, Sproull M, Goley E, Basu S, Coleman CN.
Isoprostane levels in the urine of patients with prostate cancer receiving radiotherapy are not elevated.
Int J Radiat Oncol Biol Phys. 58: 1536-9, 2004.
81)  Waselenko JK, MacVittie TJ, Blakely WF, Pesik N, Wiley AL, Dickerson WE, Tsu H, Confer DL, Coleman CN, Seed T, Lowry P, Armitage JO, Dainiak N, Strategic National Stockpile Radiation Working Group .
Medical management of the acute radiation syndrome: recommendations of the Strategic National Stockpile Radiation Working Group.
Ann Intern Med. 140: 1037-51, 2004.
82)  Coleman CN, Stone HB, Moulder JE, Pellmar TC.
Medicine. Modulation of radiation injury.
Science. 304: 693-4, 2004.
83)  Stone HB, Moulder JE, Coleman CN, Ang KK, Anscher MS, Barcellos-Hoff MH, Dynan WS, Fike JR, Grdina DJ, Greenberger JS, Hauer-Jensen M, Hill RP, Kolesnick RN, Macvittie TJ, Marks C, McBride WH, Metting N, Pellmar T, Purucker M, Robbins ME, Schiestl RH, Seed TM, Tomaszewski JE, Travis EL, Wallner PE, Wolpert M, Zaharevitz D.
Models for evaluating agents intended for the prophylaxis, mitigation and treatment of radiation injuries. Report of an NCI Workshop, December 3-4, 2003.
Radiat. Res. 162: 711-28, 2004.
84)  Menard C, Susil RC, Choyke P, Gustafson GS, Kammerer W, Ning H, Miller RW, Ullman KL, Sears Crouse N, Smith S, Lessard E, Pouliot J, Wright V, McVeigh E, Coleman CN, Camphausen K.
MRI-guided HDR prostate brachytherapy in standard 1.5T scanner.
Int J Radiat Oncol Biol Phys. 59: 1414-23, 2004.
85)  Menard C, Susil R, Coleman C.
Rad Onc's Big Boost.
Advance for Imaging and Radiation Therapy Professionals. 14: 49-50, 2004.
86)  Susil RC, Camphausen K, Choyke P, McVeigh ER, Gustafson GS, Ning H, Miller RW, Atalar E, Coleman CN, Menard C.
System for prostate brachytherapy and biopsy in a standard 1.5 T MRI scanner.
Magn Reson Med. 52: 683-7, 2004.
87)  Chan LW, Moses MA, Goley E, Sproull M, Muanza T, Coleman CN, Figg WD, Albert PS, Menard C, Camphausen K.
Urinary VEGF and MMP levels as predictive markers of 1-year progression-free survival in cancer patients treated with radiation therapy: a longitudinal study of protein kinetics throughout tumor progression and therapy.
J Clin Oncol. 22: 499-506, 2004.
88)  Wallner P, Arthur D, Bartelink H, Connolly J, Edmundson G, Giuliano A, Goldstein N, Hevezi J, Julian T, Kuske R, Lichter A, McCormick B, Orecchia R, Pierce L, Powell S, Solin L, Vicini F, Whelan T, Wong J, Coleman CN.
Workshop on partial breast irradiation: state of the art and the science, Bethesda, MD, December 8-10, 2002.
J. Natl. Cancer Inst. 96: 175-84, 2004.
89)  Marcus KJ, Dutton SC, Barnes P, Coleman CN, Pomeroy SL, Goumnerova L, Billett AL, Kieran M, Tarbell NJ.
A phase I trial of etanidazole and hyperfractionated radiotherapy in children with diffuse brainstem glioma.
Int J Radiat Oncol Biol Phys. 55: 1182-5, 2003.
90)  Menard C, Camphausen K, Muanza T, Sears-Crouse N, Smith S, Ben-Josef E, Coleman CN.
Clinical trial of endorectal amifostine for radioprotection in patients with prostate cancer: rationale and early results.
Semin. Oncol. 30: 63-7, 2003.
91)  Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, Langer C, Murphy B, Cumberlin R, Coleman CN, Rubin P.
CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment.
Semin Radiat Oncol. 13: 176-81, 2003.
92)  Colevas AD, Brown JM, Hahn S, Mitchell J, Camphausen K, Coleman CN, Radiation Modifier Working Group of the National Cancer Institute .
Development of investigational radiation modifiers.
J Natl Cancer Inst. 95: 646-51, 2003.
93)  Coleman CN, Stone HB, Alexander GA, Barcellos-Hoff MH, Bedford JS, Bristow RG, Dynlacht JR, Fuks Z, Gorelic LS, Hill RP, Joiner MC, Liu FF, McBride WH, McKenna WG, Powell SN, Robbins ME, Rockwell S, Schiff PB, Shaw EG, Siemann DW, Travis EL, Wallner PE, Wong RS, Zeman EM.
Education and training for radiation scientists: radiation research program and American Society of Therapeutic Radiology and Oncology Workshop, Bethesda, Maryland, May 12-14, 2003.
Radiat. Res. 160: 729-37, 2003.
94)  Stone HB, Coleman CN, Anscher MS, McBride WH.
Effects of radiation on normal tissue: consequences and mechanisms.
Lancet Oncol. 4: 529-36, 2003.
95)  Camphausen K, Sproull M, Tantama S, Sankineni S, Scott T, Menard C, Coleman CN, Brechbiel MW.
Evaluation of copper chelation agents as anti-angiogenic therapy.
Bioorg Med Chem. 11: 4287-93, 2003.
96)  Palayoor ST, Tofilon PJ, Coleman CN.
Ibuprofen-mediated reduction of hypoxia-inducible factors HIF-1alpha and HIF-2alpha in prostate cancer cells.
Clin Cancer Res. 9: 3150-7, 2003.
97)  Coleman CN, Wallner PE, Abrams JS.
Inflammatory breast issue.
J. Natl. Cancer Inst. 95: 1182-3, 2003.
98)  Chakraborty M, Abrams SI, Camphausen K, Liu K, Scott T, Coleman CN, Hodge JW.
Irradiation of tumor cells up-regulates Fas and enhances CTL lytic activity and CTL adoptive immunotherapy.
J Immunol. 170(12): 6338-47, 2003.
99)  Coleman CN.
Linking radiation oncology and imaging through molecular biology (or now that therapy and diagnosis have separated, it's time to get together again!).
Radiology. 228: 29-35, 2003.
100)  Coleman CN, Blakely WF, Fike JR, MacVittie TJ, Metting NF, Mitchell JB, Moulder JE, Preston RJ, Seed TM, Stone HB, Tofilon PJ, Wong RS.
Molecular and cellular biology of moderate-dose (1-10 Gy) radiation and potential mechanisms of radiation protection: report of a workshop at Bethesda, Maryland, December 17-18, 2001.
Radiat Res. 159: 812-34, 2003.
101)  Tofilon PJ, Saxman S, Coleman CN.
Molecular targets for radiation therapy: bringing preclinical data into clinical trials.
Clin Cancer Res. 9: 3518-20, 2003.
102)  Poggi MM, Cong PJ, Coleman CN, Jaffe ES.
Low-grade follicular lymphoma of the small intestine.
J. Clin. Gastroenterol. 34: 155-9, 2002.
103)  Stone HB, McBride WH, Coleman CN.
Modifying normal tissue damage postirradiation. Report of a workshop sponsored by the Radiation Research Program, National Cancer Institute, Bethesda, Maryland, September 6-8, 2000.
Radiat Res. 157: 204-23, 2002.
104)  Cumberlin RL, Coleman CN.
New directions in brachytherapy.
Int J Radiat Oncol Biol Phys. 53: 6-11, 2002.
105)  Coleman CN, Kelly L, Riese Daly N, Beard C, Kaplan I, Lamb C, Propert K, Manola J.
Phase III study of ibuprofen versus placebo for radiation-induced genitourinary side effects.
Int J Radiat Oncol Biol Phys. 54: 191-4, 2002.
106)  Coleman CN.
Radiation oncology--linking technology and biology in the treatment of cancer.
Acta Oncol. 41: 6-13, 2002.
107)  Gius D, Coleman CN.
Treatment of nasopharyngeal cancer: raising the "Barr".
J. Natl. Cancer Inst. 94: 1594-5, 2002.
108)  Coleman CN, Mitchell JB, Camphausen K.
Tumor hypoxia: chicken, egg, or a piece of the farm?.
J Clin Oncol. 20: 610-5, 2002.
109)  Coleman CN.
International Conference on Translational Research and Preclinical Strategies in Radio-Oncology (ICTR)--conference summary.
Int. J. Radiat. Oncol. Biol. Phys. 49: 301-9, 2001.
110)  Coleman CN.
Investing in our future: listening to those who will take us where we need to go.
Int. J. Radiat. Oncol. Biol. Phys. 49: 1211, 2001.
111)  Cumberlin RL, Coleman CN.
Research in medical physics.
Int. J. Radiat. Oncol. Biol. Phys. 49: 891-5, 2001.
112)  Poggi MM, Coleman CN, Mitchell JB.
Sensitizers and protectors of radiation and chemotherapy.
Curr Probl Cancer. 25: 334-411, 2001.
113)  Coleman CN, Cumberlin RL.
Translational research in radiation oncology.
Int. J. Radiat. Oncol. Biol. Phys. 49: 885-90, 2001.
114)  Coleman CN, Cumberlin R.
We're from the government and we're here to help you.
Int. J. Radiat. Oncol. Biol. Phys. 49: 617-8, 2001.
115)  Coleman CN.
Young Investigators Workshop--Radiation Research Program, Radiation Oncology Sciences Program, National Cancer Institute, NIH, August 1-2 2000.
Int. J. Radiat. Oncol. Biol. Phys. 49: 1505-16, 2001.
116)  Hussey DH, Sagerman RH, Halberg F, Dubey A, Coleman CN.
Report of the 1997 SCAROP survey on resident training. Society of Chairmen of Academic Radiation Oncology Programs.
Acad Radiol. 7: 176-83, 2000.
117)  Coleman CN, Govern FS, Svensson G, Mitchell R, Chaffey JT.
The Harvard Joint Center for Radiation Therapy, 1968-1999: a unique concept and its relationship to the prevailing times in academic medicine.
Int J Radiat Oncol Biol Phys. 47: 1357-69, 2000.
118)  Coleman CN, Mitchell JB.
Clinical radiosensitization: why it does and does not work.
J. Clin. Oncol. 17: 1-3, 1999.
119)  Palayoor ST, Youmell MY, Calderwood SK, Coleman CN, Price BD.
Constitutive activation of IkappaB kinase alpha and NF-kappaB in prostate cancer cells is inhibited by ibuprofen.
Oncogene. 18: 7389-94, 1999.
120)  Coleman CN, Mason T, Hooker EP, Robinson SE.
Developmental effects of intermittent prenatal exposure to 1,1,1-trichloroethane in the rat.
Neurotoxicol Teratol. 21: 699-708, 1999.
121)  Coleman CN.
Molecular biology in radiation oncology. Radiation oncology perspective of BRCA1 and BRCA2.
Acta Oncol. 38 Suppl 13: 55-9, 1999.
122)  Shulman LN, Buswell L, Riese N, Doherty N, Loeffler JS, von Roemeling RW, Coleman CN.
Phase I trial of the hypoxic cell cytotoxin tirapazamine with concurrent radiation therapy in the treatment of refractory solid tumors.
Int. J. Radiat. Oncol. Biol. Phys. 44: 349-53, 1999.
123)  D'Amico AV, Whittington R, Malkowicz SB, Fondurulia J, Chen MH, Kaplan I, Beard CJ, Tomaszewski JE, Renshaw AA, Wein A, Coleman CN.
Pretreatment nomogram for prostate-specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer.
J. Clin. Oncol. 17: 168-72, 1999.
124)  Stevenson MA, Zhao MJ, Asea A, Coleman CN, Calderwood SK.
Salicylic acid and aspirin inhibit the activity of RSK2 kinase and repress RSK2-dependent transcription of cyclic AMP response element binding protein- and NF-kappa B-responsive genes.
J. Immunol. 163: 5608-16, 1999.
125)  Linggood R, Govern F, Coleman CN.
A blueprint for linking academic oncology and the community.
J Health Polit Policy Law. 23: 973-94, 1998.
126)  D'Amico AV, Whittington R, Kaplan I, Beard C, Schultz D, Malkowicz SB, Wein A, Tomaszewski JE, Coleman CN.
Calculated prostate carcinoma volume: The optimal predictor of 3-year prostate specific antigen (PSA) failure free survival after surgery or radiation therapy of patients with pretreatment PSA levels of 4-20 nanograms per milliliter.
Cancer. 82: 334-41, 1998.
127)  Coleman CN.
Chemical sensitizers and protectors.
Int. J. Radiat. Oncol. Biol. Phys. 42: 781-3, 1998.
128)  Palayoor ST, Bump EA, Calderwood SK, Bartol S, Coleman CN.
Combined antitumor effect of radiation and ibuprofen in human prostate carcinoma cells.
Clin. Cancer Res. 4: 763-71, 1998.
129)  Coleman CN, Harris JR.
Current scientific issues related to clinical radiation oncology.
Radiat. Res. 150: 125-33, 1998.
130)  Teicher BA, Ara G, Chen YN, Recht A, Coleman CN.
Interaction of tomudex with radiation in vitro and in vivo.
Int. J. Oncol. 13: 437-42, 1998.
131)  Stone HB, Dewey WC, Wallace SS, Coleman CN.
Molecular Biology to Radiation Oncology: A Model for Translational Research? Opportunities in basic and translational research. From a workshop sponsored by the National Cancer Institute, Radiation Research Program, January 26-28, 1997, Bethesda, Maryland.
Radiat. Res. 150: 134-47, 1998.
132)  Coleman CN.
Of what use is molecular biology to the practicing radiation oncologist?.
Radiother Oncol. 46: 117-25, 1998.
133)  D'Amico AV, Cormack R, Tempany CM, Kumar S, Topulos G, Kooy HM, Coleman CN.
Real-time magnetic resonance image-guided interstitial brachytherapy in the treatment of select patients with clinically localized prostate cancer.
Int. J. Radiat. Oncol. Biol. Phys. 42: 507-15, 1998.
134)  Chang EL, Loeffler JS, Riese NE, Wen PY, Alexander E, Black PM, Coleman CN.
Survival results from a phase I study of etanidazole (SR2508) and radiotherapy in patients with malignant glioma.
Int. J. Radiat. Oncol. Biol. Phys. 40: 65-70, 1998.
Click Here to View Collapsed Bibliography.

This page was last updated on 6/13/2014.